ZYDUS CADILA TO BEGIN TRIALS OF ZYH1 IN INDIA

A A

Cadila Healthcare has announced that the company received permission from the Drug Controller General of India to conduct Phase II clinical trials on its new molecular entity ZYH1, after successfully completing Phase I clinical trials.

The Phase II studies would focus on evaluating the efficacy of ZYH1. ZYH1 is expected to address the issue related to patients suffering from dyslipidemia in both diabetic and non-diabetic condition.